Global Lidocaine Ointment Market, by Formulation (Internal Use and Topical Use), by Age Group (Children and Adult), by Application (Insect Bite, Sun Burn, Minor Cut, Mouth Sore, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,275.2 Million in 2022 and is expected to exhibit a CAGR of 7.7% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Lidocaine ointment is used for pain relief after various medical procedures such as cosmetics surgery. Thus, an increase in the number of cosmetic surgeries can increase the demand for lidocaine ointment over the forecast period. For instance, in February 2022, according to the data provided by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the association of facial plastic surgeons, 1.4 million surgical and non-surgical procedures had been done in 2020. The number of cosmetic procedures was increased by 40% in 2021.
Global Lidocaine Ointment Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019," or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.
The COVID-19 had a positive impact on the global lidocaine ointment market, owing to its application in the COVID-19-pandemic-associated symptoms such as atrial fibrillation and supraventricular tachycardia. For instance, in May 2020, according to an article published by the National Library of Medicine, there was 355 COVID-19 patients in Italy among them 24.5% patients had atrial fibrillation symptom. Thus, COVID-19 had a positive impact on the lidocaine ointment market.
Global Lidocaine Ointment Market: Key Developments
In August 2022, Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to investigational drug and product candidate SP-103. Scilex was developing SP-103 as a non-opioid, triple strength, non-aqueous lidocaine topical system for the treatment of lower back pain.